On February 24, 2022 Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, reported that Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will present at the following investor and industry conferences (Press release, Synlogic, FEB 24, 2022, View Source [SID1234608931]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan’s 3rd Annual Microbiome Medicines Summit: Dr. Brennan will participate in a fireside chat at 2:30 pm EST and in a panel discussion at 3:15 pm EST on Tuesday, March 1, 2022. The panel discussion is entitled "Great Debate – Is the Term ‘Microbiome’ Drug Development Now Passé?", and both programs will be held virtually.
Oppenheimer’s 32nd Annual Healthcare Conference: Dr. Brennan will present virtually at 10:40 am EST on Thursday, March 17, 2022.
Live webcasts of the presentations, if available, will be accessible under the "Event Calendar" in the Investors & Media section of the Company’s website. Archived versions of webcasts will also be available after the program on the Synlogic website.